Key result
Torsemide was not associated with a significant difference in intermediate-term mortality compared with furosemide, but reduced heart failure readmissions.
Why the study?
Loop diuretics are a mainstay of chronic heart failure management, but evidence regarding the optimal choice between furosemide and torsemide for clinical outcomes remains inconsistent.
Does oral torsemide improve intermediate-term outcomes compared to oral furosemide in patients with chronic heart failure?
Meta-Analysis (n=8,127)
Does oral torsemide improve intermediate-term outcomes compared to oral furosemide in patients with chronic heart failure?
In patients with chronic heart failure, torsemide is associated with reduced heart failure readmissions and improved NYHA class compared to furosemide, though without a significant difference in intermediate-term mortality.
Answers are grounded in this paper and cite their sources.
Torsemide may improve NYHA class versus furosemide in HF; leaves open effects on mortality or hospitalizations.
AIMS: Loop diuretics have become a mainstay of chronic heart failure management. Furosemide and torsemide are the two most common loop diuretics; nevertheless, there is inconsistent evidence regarding the optimal choice of loop diuretic with respect to clinical outcomes. METHODS: Medline and Cochrane Databases were systemically reviewed for randomized and observational studies comparing patients with chronic heart failure on oral torsemide versus oral furosemide and their association with intermediate-term outcomes (5-12 months) through May 2018. Odds ratios with corresponding 95% confidence intervals (CIs) were used for outcomes. A random effect model was used to account for heterogeneity among studies. Heterogeneity was assessed with the Higgins I-square statistic. RESULTS: A total of 8127 patients were included in the analysis from a total of 14 studies (10 randomized, four observational); 5729 patients were prescribed furosemide and 2398 were given torsemide. There was no significant difference in intermediate-term mortality among heart failure patients on furosemide compared with torsemide [odds ratio (OR) 1.01, CI 0.64-1.59, I = 65.8%]; however, furosemide was associated with an increased risk of heart failure readmissions (OR 2.16, CI 1.28-2.64, I = 0.0%). Heart failure patients taking torsemide were more likely to have an improvement in New York Heart Association class compared with those on furosemide (OR 0.73, CI 0.58-0.93, I = 19.6%). CONCLUSION: Torsemide is associated with a reduction in intermediate-term heart failure readmissions and improvement in New York Heart Association class compared with furosemide but is not associated with a reduced mortality risk. Additional randomized trials are needed to examine the impact of loop diuretics on clinical outcomes in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Miles et al. (2019) conducted a meta-analysis in chronic heart failure (n=8,127). Torsemide vs. Furosemide was evaluated on intermediate-term mortality (OR 1.01, 95% CI 0.64-1.59). Torsemide was not associated with a significant difference in intermediate-term mortality compared with furosemide, but reduced heart failure readmissions.
Synapse has enriched 10 related papers. Consider them for comparative context: